(Updated - August 14, 2018 8:29 AM EDT)(updated to correct rating)Citi analyst Joel Beatty initiated coverage on Sarepta Therapeutics (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE